These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28287807)

  • 1. All-Cause and Cardiovascular Mortality following Treatment with Metformin or Glyburide in Patients with Type 2 Diabetes Mellitus.
    Raee MR; Nargesi AA; Heidari B; Mansournia MA; Larry M; Rabizadeh S; Zarifkar M; Esteghamati A; Nakhjavani M
    Arch Iran Med; 2017 Mar; 20(3):141-146. PubMed ID: 28287807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
    Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up.
    Fisman EZ; Tenenbaum A; Boyko V; Benderly M; Adler Y; Friedensohn A; Kohanovski M; Rotzak R; Schneider H; Behar S; Motro M
    Clin Cardiol; 2001 Feb; 24(2):151-8. PubMed ID: 11460818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
    Diabetes Obes Metab; 2012 Sep; 14(9):803-9. PubMed ID: 22486923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin in combination with various insulin secretagogues in type 2 diabetes and associated risk of cardiovascular morbidity and mortality--a retrospective nationwide study.
    Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
    Diabetes Res Clin Pract; 2015 Jan; 107(1):104-12. PubMed ID: 25458330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients.
    Bo S; Castiglione A; Ghigo E; Gentile L; Durazzo M; Cavallo-Perin P; Ciccone G
    Eur J Endocrinol; 2013 Jul; 169(1):117-26. PubMed ID: 23660643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study.
    Roumie CL; Hung AM; Greevy RA; Grijalva CG; Liu X; Murff HJ; Elasy TA; Griffin MR
    Ann Intern Med; 2012 Nov; 157(9):601-10. PubMed ID: 23128859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-cause mortality and cardiovascular effects associated with the DPP-IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population.
    Scheller NM; Mogensen UM; Andersson C; Vaag A; Torp-Pedersen C
    Diabetes Obes Metab; 2014 Mar; 16(3):231-6. PubMed ID: 24020750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
    Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
    Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis.
    Han Y; Xie H; Liu Y; Gao P; Yang X; Shen Z
    Cardiovasc Diabetol; 2019 Jul; 18(1):96. PubMed ID: 31362743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular, metabolic and hormonal responses to the progressive exercise performed to exhaustion in patients with type 2 diabetes treated with metformin or glyburide.
    Cunha MR; Silva ME; Machado HA; Fukui RT; Correia MR; Santos RF; Wajchenberg BL; Rocha DM; Rondon MU; Negrão CE; Ursich MJ
    Diabetes Obes Metab; 2008 Mar; 10(3):238-45. PubMed ID: 18269639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The risk of overall mortality in patients with Type 2 diabetes receiving different combinations of sulfonylureas and metformin: a retrospective analysis.
    Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Nutter B; Jain A; Atreja A; Zimmerman RS
    Diabet Med; 2012 Aug; 29(8):1029-35. PubMed ID: 22248043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metformin monotherapy on cardiovascular diseases and mortality: a retrospective cohort study on Chinese type 2 diabetes mellitus patients.
    Fung CS; Wan EY; Wong CK; Jiao F; Chan AK
    Cardiovasc Diabetol; 2015 Oct; 14():137. PubMed ID: 26453464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial.
    Ghotbi AA; Køber L; Finer N; James WP; Sharma AM; Caterson I; Coutinho W; Van Gaal LF; Torp-Pedersen C; Andersson C
    Diabetes Care; 2013 Nov; 36(11):3746-53. PubMed ID: 24089540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
    Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
    Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus.
    Li T; Providencia R; Mu N; Yin Y; Chen M; Wang Y; Liu M; Yu L; Gu C; Ma H
    Cardiovasc Diabetol; 2021 Jan; 20(1):30. PubMed ID: 33516224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes.
    Rosiak M; Postula M; Kaplon-Cieslicka A; Trzepla E; Czlonkowski A; Filipiak KJ; Opolski G
    Adv Med Sci; 2013; 58(2):362-8. PubMed ID: 24327531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
    Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
    Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin therapy in patients with diabetes mellitus is associated with a reduced risk of vasculopathy and cardiovascular mortality after heart transplantation.
    Ram E; Lavee J; Tenenbaum A; Klempfner R; Fisman EZ; Maor E; Ovdat T; Amunts S; Sternik L; Peled Y
    Cardiovasc Diabetol; 2019 Sep; 18(1):118. PubMed ID: 31526382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.